識別子と物理属性
| CAS No. | 234447-17-7 |
|---|
| 分子式 | C13H19Cl2NO |
|---|
| 平均分子量 | 276.2 g/mol |
|---|
| 単同位体質量 | 275.08436959 g/mol |
|---|
| SMILES | CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl |
|---|
| InChIKey | HEYVINCGKDONRU-UHFFFAOYSA-N |
|---|
| PubChem CID | 62884 |
|---|
| ChEMBL | CHEMBL1698 |
|---|
| ChEBI | CHEBI:3220 |
|---|
| EC No. | 250-759-9 |
|---|
| DTXSID | DTXSID6044561 |
|---|
化学・物理的性質
| 極性表面積 | 29.1 |
|---|
| 水素結合供与体数 | 2 |
|---|
| 水素結合受容体数 | 2 |
|---|
| 回転可能結合数 | 4 |
|---|
| 重原子数 | 17 |
|---|
| 形式電荷 | 0 |
|---|
| 複雑度 | 247 |
|---|
| Human Drugs | Breast FeedingLactationMilk, HumanAntidepressive AgentsAntidepressive Agents, Second-GenerationDopamine Uptake InhibitorsSmoking Cessation AgentsFDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
|---|
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 48.1% (52 of 108) of reports.WarningH302 (51.9%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 108 reports by companies from 10 notifications to the ECHA C&L Inventory. |
|---|
| Hazard Classes and Categories | Acute Tox. 4 (51.9%) |
|---|
| Treatment | Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. EEG monitoring is also recommended for the first 48 hours post-ingestion. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hemoperfusion, or exchange transfusion in the management of bupropion overdoses. No specific antidotes for bupropion are known. Due to the dose-related risk of seizures with Bupropion, hospitalization following suspected overdose should be considered. Based on studies in animals, it is recommended that seizures be treated with intravenous benzodiazepine administration and other supportive measures, as appropriate. (L1712) |
|---|
| 暴露経路 | For sustained release, peak plasma concentrations are achieved within 3 hours. |
|---|
| 毒性の概要 | Bupropion selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotoninactions on dopaminergic systems are more significant than imipramine or amitriptyline whereas the blockade of norepinephrine and serotonin reuptake at the neuronal membrane is weaker for bupropion than for tricyclic antidepressants. The increase in norepinephrine may attenuate nicotine withdrawal symptoms and the increase in dopamine at neuronal sites may reduce nicotine cravings and the urge to smoke. Bupropion exhibits moderate anticholinergic effects. |
|---|
| Signs and Symptoms | Symptoms of overdose include seizures, hallucinations, loss of consciousness, tachycardia, and cardiac arrest. |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Bupropion hydrochloride |
|---|
